Fusion Antibodies is a Contract Research Organisation (CRO) that provides a range of service in the area of antibody engineering for the development of antibodies for both therapeutic drug and diagnostic applications. Focusing on antibody generation, development, production, characterisation and optimisation, these services include antigen expression, antibody production, purification and sequencing, antibody humanisation using the Company's proprietary CDRx(TM) platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced over 250 antibodies and successfully completed over 215 humanisation projects for its clients with 8 out of the first 33 humanisation projects
Headquartered in Belfast, Northern Ireland, the Company was established in 2001 as a spin out from Queen's University. It was initially a drug development business but revised its operations to focus on CRO work in 2011. The company has over 20 employees and was listed on AIM in December 2017. The company has ambitious plans to grow with a strategy based on the expansion of its client base as well as the addition of new service offerings. This strategy uses the Company's proven technology and expertise and targets expansion both in the UK market and internationally. Key new service offerings being developed include antibody affinity maturation and a Mammalian Antibody Library Discovery Platform which represent key future growth drivers.
Fusion is at a key value inflection point in the Company's evolution with a key focus on expanding/driving current commercial performance and accessing additional value generating opportunities as well as launch preparations for the new service offerings.
MNCJobs.co.uk will not be responsible for any payment made to a third-party. All Terms of Use are applicable.